NBIX:NASDAQ
Neurocrine Biosciences, Inc
၁၃၆.၉၅ US$
arrow_upward
+၀.၇၇%(+၁.၀၄) 1D
၁၃၆.၉၅ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: အောက် ၁၅, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
၁၃၇.၂၆ US$
High
၁၃၈.၂၃ US$
Low
၁၃၅.၅၅ US$
Mkt. cap
ဋေ ၁.၃၉ ထ
Avg. vol.
၁.၃၁ သန်း
Volume
၁.၃၈ သန်း
P/E ratio
၂၀.၀၈
52-wk high
၁၈၆.၁၂ US$
52-wk low
၁၂၂.၁၄ US$
EPS
၆.၈၂ US$
Beta
၀.၄၀
Shares outstanding
၁၀.၁၆ ကုဋေ
No. of employees
၂ ထောင်
Open
၁၃၇.၂၆ US$
High
၁၃၈.၂၃ US$
Low
၁၃၅.၅၅ US$
Mkt. cap
ဋေ ၁.၃၉ ထ
Avg. vol.
၁.၃၁ သန်း
Volume
၁.၃၈ သန်း
P/E ratio
၂၀.၀၈
52-wk high
၁၈၆.၁၂ US$
52-wk low
၁၂၂.၁၄ US$
EPS
၆.၈၂ US$
Beta
၀.၄၀
Shares outstanding
၁၀.၁၆ ကုဋေ
No. of employees
၂ ထောင်
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၇ နာရီ
RBC keeps USD 187.00 target for Neurocrine Biosciences stock
Stock Titan
·
ပြီးခဲ့သည့် ၇ နာရီ
JPMorgan reports a passive stake in Neurocrine Biosciences (NBIX)
Investing.com
·
ပြီးခဲ့သည့် ၁ ရက်
TD Cowen reiterates Neurocrine Bio stock rating on growth outlook
Zacks
·
ပြီးခဲ့သည့် ၁ ရက်
Why Neurocrine Biosciences (NBIX) is a Top Value Stock for the Long-Term
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees၂.၅ ထောင်
Founded၁၉၉၂
Headquartersဆန်ဒီရေဂို, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteneurocrine.com